Key statistics dashboard for HCW Biologics Inc. (HCWB). Valuation multiples (P/E, P/B, EV/EBITDA), profitability margins, financial-health ratios, per-share metrics and stock-level data in one consolidated view — the snapshot quantitative analysts and value investors check first.
HCW Biologics Inc. operates as a preclinical-stage biopharmaceutical firm, primarily engaged in the discovery and advancement of novel immunotherapies. Its research and development efforts are focused on addressing chronic, low-grade inflammation and a spectrum of age-related diseases.
Stock Data
| Price | $2.01 |
| Market Cap | $1M |
| Enterprise Value | $6.5M |
| Exchange | NASDAQ |
| Country | US |
Valuation Multiples
| P/E Ratio | -0.04 |
| Price / Book | 0.10 |
| P/S | 0.11 |
| EV/EBITDA | -1.53 |
| EV/Sales | 0.97 |
| EV/FCF | -0.54 |
| P/FCF | -0.06 |
| Earnings Yield | -700.34% |
| FCF Yield | -1736.91% |
| Dividend Yield | 0.00% |
Profitability
| Gross Margin | 95.91% |
| EBIT Margin | -72.49% |
| EBITDA Margin | -63.56% |
| Operating Margin | -91.57% |
| Net Margin | -73.22% |
| Return on Equity | -142.16% |
| Return on Assets | -18.39% |
| Return on Invested Capital | -39.28% |
| Return on Capital Employed | -75.79% |
Financial Health
| Current Ratio | 0.06 |
| Quick Ratio | 0.06 |
| Cash Ratio | 0.04 |
| Debt / Equity | 0.88 |
| Debt / Assets | 24.51% |
| Net Debt / EBITDA | -1.36 |
| Interest Coverage | -17.08 |
| Piotroski F-Score | 3 |
| Altman Z-Score | -8.57 |
Per-Share Data
| Revenue per share | 19.22 |
| Book Value per share | 21.25 |
| Cash per share | 2.12 |
| FCF per share | -34.71 |
| Tangible Book Value per share | 21.25 |
| Dividend per share | 0.00 |
Analyst Consensus
| Strong Buy | 0 |
| Buy | 3 |
| Hold | 0 |
| Sell | 0 |
| Strong Sell | 0 |
| Total analysts | 3 |
| Avg rating (1-5) | 1.00 |
Related companies: ACXP · ADIL · APRE · APVO · BCDA · BCLI · CELZ
Explore sector: Healthcare · Biotechnology
More sections of HCWB: Overview · Financials · Valuation · Estimates · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks